Type 2 diabetes affects around 480 million people worldwide, and is predicted to increase to 700 million by 2045. Another half a billion people have impaired glucose tolerance or pre-diabetes, or higher than normal blood sugar levels that, if left untreated, can develop into Type 2 diabetes.
Some studies have shown that Vitamin D deficiency is associated with an increased risk of future diabetes, but trials of Vitamin D supplements for preventing the condition have shown inconsistent results. The new study, published by The BMJ, shows that supplements had no clinically meaningful effect in high-risk adults, but suggests there may be a benefit for people with insufficient insulin secretion, although this finding remains unclear.
In the study, the team assessed whether eldecalcitol - an active form of vitamin D used to treat osteoporosis in Japan - could reduce the risk of developing Type 2 diabetes among people with impaired glucose tolerance. They analysed 1,256 Japanese adults with impaired glucose tolerance recruited from three hospitals in Japan and were divided into two groups: a standard daily dose of eldecalcitol (630 participants) or placebo (626 participants). They were assessed for diabetes every three months over a three-year follow-up period.